powerful enough to overcome the established trend toward "arthroscopification" of most knee surgery. During an initial period of intense enthusiasm, hundreds of surgeons hastened to complete the specialized training required to accomplish the new procedure. some of them undoubtedly needing to refresh neglected arthrotomy skills.
Just as Star Trek helped rekindle popular ardor for the venerable genre of science fiction. ACI contributed to a renewal of general interest in the surgical treatment of articular cartilage defects. Time-honored techniques for stimulating healing, such as drilling and abrasion, were updated to the concept of microfracture. The idea of transplanting autogenous or allogenic osteochondral composites spread from a few core pioneers to a much wider public of practicing surgeons. Suddenly, there were treatment options for lesions that had often been dismissed as inconsequential if small or hopeless if large.
As with any new surgical technique, the initial enthusiasm for ACI was eventually moderated by a growing awareness of its inherent limitations and potential complications. The inescapable facts that ACI required 2 surgical procedures, including an arthrotomy and periosteal harvest, and was technically demanding, not to mention costly, served to temper the passion of many practitioners. The availability of the alternatives just mentioned gave surgeons other choices that could be accomplished in a single relatively economical arthroscopic procedure without incurring the additional risk of periosteal overgrowth. The 2004 publication by Knutsen et aI' of a randomized controlled trial comparing ACI and microfracture caught the attention of the orthopaedic community when it found little difference between the 2 alternative procedures, either in the nature of the reparative tissue produced or the clinical outcome at 2 years.
Just as diehard Trekkies never lost their passion fOJ' the voyages of the starship Enterprise, aficionados of ACI have not abandoned the procedure. Instead, they have worked to overcome the limitations of the original technique and improve its ability to fulfill the promise of regenerating true hyaline cartilage. This has led to a number of proposed innovations that Gene Roddenberry might dub ACl: The Next Generation. Initiatives such as chondrocyte-seeded scaffolds and scaffold-free cellular constructs promise to eliminate the painstaking process of affixing a periosteal cover, thereby reducing operating time, eliminating the risk of periosteal overgrowth, and facilitating arthroscopic implantation.l':" Other innovations are designed to improve the ability of the procedure to regenerate true hyaline cartilage. 1.2 In this issue, Saris et al relate the early results of a randomized controlled trial comparing one of these new techniques, characterized chondrocyte implantation (CCI). with microfracture in the treatment of symptomatic cartilage defects of the femoral condyles. Characterized chondrocyte implantation brings eugenics to a cellular level by selecting cultured chondrocytes thought to be genetically programmed to generate hyaline-like cartilage.
Like the crew of the Enterprise, the authors of this study are a diverse team of intrepid scientists who transcend international borders. Saris and colleagues randomized 118 patients with symptomatic isolated cartilage lesions between the 2 treatments. They assessed their results with tissue biopsies at 1 year and Knee injury and Osteoarthritis Outcome Score (KOOS) (excluding the sports domain) at 6, 12, and 18 months following implantation. Histological evaluation was performed by blinded personnel at a neutral site with histomorphometric measurement of safranin-O staining and anticollagen II antibody uptake, as well as an overall structural histology assessment rating. The CCI group demonstrated higher histomorphometry and overall histology assessment scores than the microfracture group, while both groups showed similar improvement in the KOOS clinical outcome scores at all time points. Still requiring a periosteal covering, the new technique did not eliminate the risk of tissue overgrowth, with 7 patients in the CCI group exhibiting symptomatic hypertrophy.
Ultimately, researchers will need to show that the added expense of higher levels of technology will he justified by clinical outcomes that are clearly superior to the results of lower-tech, single-stage procedures. Although Star Trek's Mr Spock would probably propose that a connection between more normal tissue structure and improved longterm outcome seems logical, it has yet to be proven conclusively. Reporting their 5-year results, Knutsen et al'' were unable to demonstrate a correlation between the histology results at 2 years and the clinical outcome at 5 years, although they noted that none of the patients with the highest tissue quality went on to clinical failure.
Although Saris and colleagues' results showed that the CCI group was superior in many parameters of cartilage morphology compared with the microfracture group, they still did not invariably demonstrate perfectly normal hyaline cartilage structure. Cartilage replacements seem to require an extended time frame and properly modulated activity levels to achieve optimal structure.i" so J-year biopsies probably do not tell the final story. Newer MRI techniques may allow investigators to re-evaluate cartilage quality periodically without the need for invasive biopsies." Like Star Trek and its subsequent generations of progeny, the saga ofCCI and the many other descendents of The American Journal of Sports Medicine ACI will need to be reviewed for many seasons before we will be fully able to appreciate the magnitude of their impact.
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